Wednesday, February 27, 2019 9:24:49 PM
Does IGC have $40 million in public shares? Or $39 million? If this is the case, would IGC be compliant with NYSE qualification? Would it be possible the re-list of IGC is a one-timer looking for revenge, along with, a unanimous flip?
It's hard to scope anything with having no updated product material published for review.
Initial Listing
To qualify for listing on the NYSE, a company must have at least 400 shareholders, with at least 1.1 million shares available to the public and a market value of the public shares of at least $40 million. Each stock must have a minimum value of $4 at the time of listing.
Minimum Trading Price
Once a stock is listed, its price is determined by public trading on the NYSE floor, where bids to buy and offers to sell are matched. The stock's price fluctuates as investors assess its worth. NYSE stocks must maintain a minimum price of $1 per share.
Minimum Penalty
If a listed stock closes or ends the trading day below $1 for 30 consecutive days, it is a candidate for delisting or removal from NYSE trading. The NYSE typically suspends trading in the stock after the 30th day that it averages below $1 per share. This happened to Eastman Kodak in January 2012, when it fell toward bankruptcy.
Minimum Suspension
The NYSE at times has suspended its minimum price requirement. In 2009, for instance, it dropped the $1 per share minimum requirement from March through June due to a significant decline in trading prices of many listed companies.
https://finance.zacks.com/minimum-stock-price-nyse-5116.html
It's hard to scope anything with having no updated product material published for review.
Initial Listing
To qualify for listing on the NYSE, a company must have at least 400 shareholders, with at least 1.1 million shares available to the public and a market value of the public shares of at least $40 million. Each stock must have a minimum value of $4 at the time of listing.
Minimum Trading Price
Once a stock is listed, its price is determined by public trading on the NYSE floor, where bids to buy and offers to sell are matched. The stock's price fluctuates as investors assess its worth. NYSE stocks must maintain a minimum price of $1 per share.
Minimum Penalty
If a listed stock closes or ends the trading day below $1 for 30 consecutive days, it is a candidate for delisting or removal from NYSE trading. The NYSE typically suspends trading in the stock after the 30th day that it averages below $1 per share. This happened to Eastman Kodak in January 2012, when it fell toward bankruptcy.
Minimum Suspension
The NYSE at times has suspended its minimum price requirement. In 2009, for instance, it dropped the $1 per share minimum requirement from March through June due to a significant decline in trading prices of many listed companies.
https://finance.zacks.com/minimum-stock-price-nyse-5116.html
Recent IGC News
- IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase • ACCESS Newswire • 04/28/2026 04:15:00 PM
- IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion • ACCESS Newswire • 04/22/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/20/2026 08:01:33 PM
- IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia • ACCESS Newswire • 04/20/2026 12:30:00 PM
- IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout • ACCESS Newswire • 04/14/2026 12:30:00 PM
- Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts • ACCESS Newswire • 04/08/2026 04:45:00 PM
- IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease • ACCESS Newswire • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:02:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:01:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:43:01 PM
- IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness • ACCESS Newswire • 03/30/2026 12:00:00 PM
- IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 • ACCESS Newswire • 03/19/2026 01:00:00 PM
- IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 • ACCESS Newswire • 03/18/2026 01:00:00 PM
- IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research • ACCESS Newswire • 02/26/2026 01:30:00 PM
- IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets • ACCESS Newswire • 02/24/2026 01:30:00 PM
- IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial • ACCESS Newswire • 02/23/2026 01:30:00 PM
- IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances • ACCESS Newswire • 02/17/2026 01:30:00 PM
- IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets • ACCESS Newswire • 02/12/2026 01:30:00 PM
- IGC Pharma Announces Equity Research Update by Alliance Global Partners • ACCESS Newswire • 02/10/2026 01:30:00 PM
- IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center • ACCESS Newswire • 02/09/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 09:02:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/08/2025 05:15:14 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/03/2025 09:05:25 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/14/2025 10:27:11 PM
